Prilenia signs deal for former Teva ALS drug worth up to 500m
Israeli-Dutch scientific stage biotech firm Prilenia Therapeutics has introduced a collaboration and licensing settlement for its lead drug Pridopidine, ...
Wednesday, May 6, 2026
Tag: ALS
NeuroSense schedules FDA meeting for ALS drug trial By Investing.com
CAMBRIDGE, Mass. - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biotech agency specializing in neurodegenerative illness therapies, has secured a Kind ...
RECOMMENDED
UBS raises Church & Dwight stock price target on strong earnings By Investing.com
Investing.com - UBS raised its value goal on Church & Dwight Co. Inc. (NYSE:CHD) shares to $100 from $98 whereas...
Copyright © 2024 PWC.